Exploring lung health and immune system in a rare muscle disease
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with dermatomyositis, a condition that causes muscle inflammation and skin rashes
- You tested positive for anti-MDA5 antibodies (a specific blood marker linked to lung problems)
- You have a type of lung disease called rapidly progressive interstitial lung disease (RPILD) linked to your condition
- You are 18 years old or older
- You have agreed to take part in this study and signed a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
This trial tests if emapalumab can help people with a serious lung condition linked to MDA5 antibodies. It may be an option for those with worsening breathing despite other treatments.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This study collects health information and may store blood or other samples to learn more about interstitial lung disease (ILD) and autoimmune-related conditions. Joining could help researchers understand different causes of ILD and improve future care.
Hear when a new Microbiome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.